HKD68.55
0.94% today
Hong Kong, Apr 02, 10:08 am CET
ISIN
CNE1000031K4
Symbol
2359
Index
Sector
Industry

WuXi AppTec Stock price

HKD68.55
+9.45 15.99% 1M
+4.40 6.86% 6M
+12.05 21.33% YTD
+31.80 86.53% 1Y
-68.05 49.82% 3Y
+10.63 18.36% 5Y
+39.64 137.10% 10Y
Hong Kong, Closing price Wed, Apr 02 2025
-0.65 0.94%
ISIN
CNE1000031K4
Symbol
2359
Index
Sector
Industry

Key metrics

Market capitalization HKD198.75b
Enterprise Value HKD187.48b
P/E (TTM) P/E ratio 19.69
EV/Sales (TTM) EV/Sales 4.56
P/S ratio (TTM) P/S ratio 4.83
P/B ratio (TTM) P/B ratio 3.28
Dividend yield 1.52%
Last dividend (FY24) HKD1.43
Revenue growth (TTM) Revenue growth -7.67%
Revenue (TTM) Revenue HKD41.11b
EBIT (operating result TTM) EBIT HKD12.51b
Cash position HKD20.81b
EPS (TTM) EPS HKD3.51
P/E forward 16.11
P/S forward 4.33
EV/Sales forward 4.09
Show more

Is WuXi AppTec a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

WuXi AppTec Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a WuXi AppTec forecast:

18x Buy
86%
2x Hold
10%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a WuXi AppTec forecast:

Buy
86%
Hold
10%
Sell
5%

Financial data from WuXi AppTec

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
41,110 41,110
8% 8%
100%
- Direct Costs 23,471 23,471
11% 11%
57%
19,147 19,147
6% 6%
47%
- Selling and Administrative Expenses 3,839 3,839
134% 134%
9%
- Research and Development Expense 1,287 1,287
19% 19%
3%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 12,512 12,512
4% 4%
30%
Net Profit 12,116 12,116
3% 3%
29%

In millions HKD.

Don't miss a Thing! We will send you all news about WuXi AppTec directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China.

Head office China
CEO Min Chen
Employees 39,414
Founded 2000
Website www.wuxiapptec.com.cn

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today